Autonomix Medical’s abstract “Pain Mitigation in Pancreatic Adenocarcinoma: A Long-Term Analysis of Denervation via Transvascular RF Energy-Based Ablation” has been accepted for presentation at Digestive Disease Week 2026, which runs May 2–5 in Chicago and will also be available virtually. The session will showcase how its catheter-based microchip sensing array targets nerve pathways to alleviate severe pain in pancreatic cancer patients.

The long-term data to be presented detail sustained pain reduction metrics alongside safety findings over extended follow-up periods, demonstrating the potential of transvascular RF energy-based ablation to disrupt pain signaling without major complications. Early patient outcomes show consistent decreases in pain severity scores, reinforcing the technology’s promise in addressing a critical unmet need.

Presentation at one of the premier gastroenterology conferences underscores Autonomix’s strategy to validate its platform in front of key opinion leaders and clinicians, building credibility ahead of regulatory filings. The company plans to leverage feedback from the DDW audience to inform design of pivotal clinical trials and to advance its nerve-targeted treatment toward commercialization.